drugset / Trial / NCT00439621
Safety Study of Anti-IgE Immunotherapy in Allergic Patients
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of the study is to evaluate safety and efficacy of three doses and two dosing regimens of RP01 as an anti-IgE immunotherapy in allergic patients.
Timeline
- Start
- 2007-02
- Primary completion
- 2008-03
- Completion
- 2008-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RP 01 | Unknown | — | — |